Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
NCT ID: NCT03723668
Last Updated: 2020-05-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
94017 participants
OBSERVATIONAL
2017-10-09
2020-03-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Two major initiatives from the United Network for Organ Sharing (UNOS), the organization responsible for organ allocation in the US, failed to improve the kidney acceptance rate. First, UNOS introduced the Kidney Donor Risk Index (KDRI) for all kidney offers in 2012. The KDRI is a score that predicts survival of deceased donor kidneys based on 10 donor characteristics and was intended to simplify the process of judging organ quality for clinicians. Second, in 2014, UNOS changed the kidney allocation system so that lower-quality kidneys are offered over wider geographic areas. Despite the ongoing severe organ shortage and these allocation initiatives, the number of discarded kidneys rose from 2,127 (14.9%) in 2006 to 3,631 (20%) in 2016. In this context, the experience of transplant programs outside the US could offer novel approaches to making organ utilization more efficient through the examination of the disposition of organs that are usually discarded in the US.
This project aims:
1. To evaluate the potential benefit of transplanting kidneys that would have been discarded otherwise in the US
2. Computer simulation models on real life data to estimate the number of kidney transplants that would have taken place using data from a nationwide cohort study in two countries (France, the US);
3. To evaluate the potential gains in allograft survival years that would result in the US from a less restrictive kidney acceptance practice such as the one from France.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange
NCT03436134
Detection of Circulating Kidney DNA in Kidney Transplant Patients Facing an Episode of Graft Rejection
NCT06351488
Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions
NCT02121730
Rejection Diagnosis in Kidney Transplants Patients
NCT03582436
Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management
NCT03997253
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Main Outcome(s) and Measure(s)
In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
Graft survival will be estimated using the Kaplan-Meier method. Duration of follow-up started with the patient risk evaluation (starting point) up to the date of the kidney graft loss, defined as a patient's return to dialysis, or retransplantation. For patients who died with a functioning graft, graft survival will be censored at the time of death.
The investigators will then model kidney allograft discard practices using KDRI and perform simulation to estimate kidneys that would have been discarded in each country using the discard score (Monte-Carlo technique). The investigators will also quantify predicted kidney allograft survival of the discarded kidneys. Eventually, the investigators will estimate the gain of allograft life years based on observed survival data.
Groups/Cohorts
All kidney transplantation occurring in France and in the US from 2004 to 2014 with available data to calculate the KDRI and the Kidney Donor Profile Index (KDPI), with lower values suggestive of better quality. The KDRI and KDPI are currently used as part of the OPTN allocation system for deceased donor kidneys in the US and have been validated as reliable measures of organ quality in the US.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OPTN data system
In the US, data on the donors and kidney transplant recipients will be obtained using registry data from the Organ Procurement and Transplantation Network (OPTN). The OPTN data system includes data on all donors, waitlisted candidates, and transplant recipients in the US, as submitted by the members of the Organ Procurement and Transplantation Network. The Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services oversees the activities of the OPTN contractor.
No interventions assigned to this group
CRISTAL registry
In France, data on the donors and recipients in the French cohort will be obtained from the national CRISTAL registry, initiated in 1996 and maintained by the Agence de la Biomédecine, which prospectively collects data on all potential donors and organ transplant candidates, along with their outcomes. By law, data collection is provided by all organ procurement organizations and transplant centers in France; research studies based on the national CRISTAL registry are part of the transplant assessment activities and do not require institutional review board approval.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between January 1, 2004 and December 31, 2014.
Exclusion Criteria
* Multiorgan transplant recipients,
* Kidneys offered to transplant centers but never recovered, and
* Patients with missing data to calculate the KDRI score
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Pennsylvania
OTHER
Agence de La Biomédecine
OTHER_GOV
Paris Translational Research Center for Organ Transplantation
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter Reese, MD
Role: PRINCIPAL_INVESTIGATOR
Kidney Transplantation Care at Veteran's Affairs Medical Center
Alex Loupy
Role: PRINCIPAL_INVESTIGATOR
Paris Transplant Group, INSERM, UMR-S970, Paris, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kidney Transplantation Care at Veteran's Affairs Medical Center
Philadelphia, Pennsylvania, United States
Paris Transplant Group
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aubert O, Reese PP, Audry B, Bouatou Y, Raynaud M, Viglietti D, Legendre C, Glotz D, Empana JP, Jouven X, Lefaucheur C, Jacquelinet C, Loupy A. Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. JAMA Intern Med. 2019 Oct 1;179(10):1365-1374. doi: 10.1001/jamainternmed.2019.2322.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
USFRKT1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.